Evidence map›Paper›PMID 31419296›Full record

ArticleThe Journal of infectious diseases2019

Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M.

Damian A Oyong, Danny W Wilson, Bridget E Barber, Timothy William, Jianlin Jiang, Mary R Galinski, Freya J I Fowkes, Matthew J Grigg, James G Beeson, Nicholas M Anstey and 1 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Frontiers in immunology · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Lessons Learned for Pathogenesis, Immunology, and Disease of Erythrocytic Parasites:Frontiers in cellular and infection microbiology · 2021
    Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Damian A OyongMenzies School of Health Research, Darwin, Australia.
Danny W WilsonResearch Centre for Infectious Diseases, School of Biological Sciences, University of Adelaide, Melbourne, Australia.
Bridget E BarberMenzies School of Health Research, Darwin, Australia.
Timothy WilliamInfectious Diseases Society Kota Kinabalu, Sabah-Menzies School of Health Research Clinical Research Unit, Queen Elizabeth Hospital, Kota Kinabalu, Malaysia.
Jianlin JiangEmory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia.
Mary R GalinskiEmory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia.
Freya J I FowkesBurnet Institute, Melbourne, Australia.
Matthew J GriggMenzies School of Health Research, Darwin, Australia.
James G BeesonBurnet Institute, Melbourne, Australia.
Nicholas M AnsteyMenzies School of Health Research, Darwin, Australia.
Michelle J BoyleMenzies School of Health Research, Darwin, Australia.
Queen Elizabeth Hospital · MYEmory National Primate Research CenterMenzies School of Health Research · AUCharles Darwin University · AUMonash University · AUUniversity of Adelaide · AUUniversity of Melbourne · AU

Funding

MOLECULAR ANALYSIS OF PLASMODIUM VIVAX SURFACE ANTIGENSR01AI024710 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GALINSKI, MARY R · 1987 to 2012
$5.2M
Comparative incidence and clinical spectrum of Plasmodium knowlesi malaria, a longitudinal study in Sabah, MalaysiaR01AI116472 · NIAID · INFECTIOUS DISEASE SOCIETY KOTA KINABALU · PI WILLIAM, TIMOTHY · 2015 to 2019
$682k
NIAID NIH HHS R01 AI024710NIAID NIH HHS R01 AI116472
6 · The paper itself

Abstract

backgroundComplement-fixing antibodies are important mediators of protection against Plasmodium falciparum malaria. However, complement-fixing antibodies remain uncharacterized for Plasmodium vivax malaria. P. vivax merozoite surface protein 3α (PvMSP3α) is a target of acquired immunity and a potential vaccine candidate.

methodsPlasma from children and adults with P. vivax malaria in Sabah, Malaysia, were collected during acute infection, 7 and 28 days after drug treatment. Complement-fixing antibodies and immunoglobulin M and G (IgM and IgG), targeting 3 distinctive regions of PvMSP3α, were measured by means of enzyme-linked immunosorbent assay.

resultsThe seroprevalence of complement-fixing antibodies was highest against the PvMSP3α central region (77.6%). IgG1, IgG3, and IgM were significantly correlated with C1q fixation, and both purified IgG and IgM were capable of mediating C1q fixation to PvMSP3α. Complement-fixing antibody levels were similar between age groups, but IgM was predominant in children and IgG3 more prevalent in adults. Levels of functional antibodies increased after acute infection through 7 days after treatment but rapidly waned by day 28.

conclusionOur study demonstrates that PvMSP3α antibodies acquired during P. vivax infection can mediate complement fixation and shows the important influence of age in shaping these specific antibody responses. Further studies are warranted to understand the role of these functional antibodies in protective immunity against P. vivax malaria.

Indexed as

AdolescentAdultAgedAntibodies, ProtozoanAntigens, ProtozoanFemaleHumansImmunoglobulin GImmunoglobulin MInfant, NewbornKineticsMalaria, VivaxMaleMerozoitesMiddle AgedPlasmodium vivaxAntibodies, ProtozoanAntigens, ProtozoanImmunoglobulin GImmunoglobulin Mmerozoite surface protein 3, PlasmodiumProtozoan ProteinsComplement-fixing antibodiesmalariaPlasmodium vivaxPvMSP3α

Identifiers

PMID31419296
PMCPMC6834073
OpenAlexW2974624774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.